Lipitor's (atorvastatin) patent expiration in 2011 had a significant impact on the global market for cholesterol-lowering statin drugs. As the patent for atorvastatin came to an end in several countries, including the United States, Canada, and the European Union, generic versions of the medication began to be developed and marketed by multiple companies [1].

Generic manufacturers like Ranbaxy [2], headquartered in India, were among the first to introduce their versions of atorvastatin in several regions. This opened the floodgates for other generic versions, such as the drug manufactured by Watson Pharmaceuticals (now known as Actavis), which launched in 2010 [3]. The availability of generic Lipitor dramatically reduced prices, with the cost decreasing by over 70% [4].

A notable example of the impact is seen in Canada, where the price for atorvastatin plummeted from $100 for a 30-day supply in 2010 to under $20 in 2011, according to data from the Canadian Agency for Drugs and Technologies in Health [5]. Similar price drops were seen in other countries, making Lipitor more accessible to those in need of this medication for high cholesterol.

The reduction in price also led to increased sales for generic manufacturers as they benefited from the growing demand for affordable statin medication, allowing them to recoup their initial investments and expand their production capabilities [6].

As the Lipitor patent has continued to expire in various markets, many other generic manufacturers have entered the competition, including major pharmaceutical companies, leading to ongoing price competition DrugPatentWatch.com.

Sources:

[1] https://www.pharmtech.com/view/lipitor-patent-sunset-nears

[2] https://www.ranbaxy.com/

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021117/

[4] https://www.fiercepharma.com/pharma/lipitor-genetics-take-bid-2012

[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3051234/

[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061331/